This Article Full Text Full Text (PDF) All Versions of this Article: 90/2/775    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Baumgartner-Parzer, S. M. Articles by Vierhapper, H. Search for Related Content PubMed PubMed Citation Articles by Baumgartner-Parzer, S. M. Articles by Vierhapper, H. Related Collections Adrenal and Hypertension Pediatric Endocrinology

Carrier Frequency of Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency) in a Middle European Population

Department of Internal Medicine III (S.M.B.-P., P.N., W.W., H.V.), Division of Clinical Endocrinology and Metabolism, Medical University of Vienna, Section of Clinical Biometrics (G.H.), Medical Statistics and Informatics, Core Unit of the Medical University of Vienna, A-1090 Vienna, Austria

Address all correspondence and requests for reprints to: Sabina M. Baumgartner-Parzer, Ph.D., Department of Internal Medicine III, Division of Endocrinology, Metabolism, Waehringer Guertel 18-20, A-1090 Vienna, Austria. E-mail: sabina.baumgartner-parzer{at}meduniwien.ac.at.

Based on newborn screening data, the carrier frequency of congenital adrenal hyperplasia (CAH) in the general population has been estimated to be 1:55. The higher CAH frequency (particularly of milder forms of the disease) reported for certain populations including Yugoslavs (1.6%) relates to population genetic and hormonal data. However, so far, true carrier frequency for CAH due to 21-OH deficiency has not been determined by comprehensive mutation analysis of the 21-OH gene (CYP21A2) in an unselected European population. This study used CYP21A2 genotyping (sequence/Southern blot analysis) to determine CAH carrier frequency in a middle European (Austrian) population. The study included 100 migrants from the former Yugoslavia and 100 individuals of non-Yugoslavian origin. None of these individuals showed clinical hyperandrogenism or had a family history of CAH.

Genotyping 400 unrelated alleles from 200 clinically unaffected individuals, this study revealed a carrier frequency of 9.5%, including so-called "classic" (5.5%) and "nonclassic" (4%) CYP21A2-gene aberrations. The observed heterozygosity for CAH in Yugoslavs was not different (P = 0.8095) from that in non-Yugoslavs.

In conclusion, the observed CAH carrier frequency of 9.5% suggests a higher prevalence of CAH heterozygosity in a middle European population than hitherto estimated independently of the individuals’ Yugoslav or non-Yugoslav origin.

This article has been cited by other articles:

				R. Bergamaschi, C. Livieri, C. Uggetti, E. Candeloro, M. G. Egitto, A. Pichiecchio, V. Cosi, and S. Bastianello Brain white matter impairment in congenital adrenal hyperplasia. Arch Neurol, March 1, 2006; 63(3): 413 - 416. [Abstract] [Full Text] [PDF]